CRCT
Cricut, Inc.
CRCT's outlook is improving, though it still trails on the overall score.
MU
Micron Technology, Inc.
MU has the edge over CRCT overall, supported by stronger modeled upside and stronger valuation.
CRCT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
CRCT's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
MU Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
MU's revenue, profitability, cash flow and balance sheet are all currently strong.
CRCT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $6.15 | -28% |
| Current | 19x | $8.50 | — |
| Fair | 21x | $9.29 | +9.3% |
| Forward | 30x | $8.50 | — |
| Expensive | 34x | $15.24 | +79% |
Historical ranges are pointers, not guarantees.
CRCT has the edge over MU in the historical PE scenario, which offers more potential upside but is not a forecast.
MU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 4.6x | $798 | — |
| Cheap | 10x | $777 | -2.7% |
| Current | 11x | $798 | — |
| Fair | 22x | $1,646 | +106% |
| Expensive | 32x | $2,404 | +201% |
Historical ranges are pointers, not guarantees.
MU's PE is in its cheap range at 11x. If earnings grow as analysts expect, today's price would be 4.6x next year's earnings.
CRCT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CRCT, with profitability improving.
MU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Broad | |
| Moderate |
MU has the edge over CRCT on the outlook, with more favorable valuation expectations.
CRCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.28 | -38% |
| Q3 2026 | $0.45 | +18% |
| Q2 2026 | $0.42 | +27% |
| Q1 2026 | $0.34 | +9.7% |
| Q4 2025 | $0.35 | +21% |
| Q3 2025 | $0.38 | +36% |
| Q2 2025 | $0.33 | +6.5% |
| Q1 2025 | $0.31 | +6.9% |
| Q4 2024 | $0.29 | +21% |
CRCT's earnings per share have fallen from their peak: $0.45 over the past year, against $0.95 in mid-2021.
MU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $174.95 | +135% |
| Q3 2026 | $74.33 | +879% |
| Q2 2026 | $44.17 | +693% |
| Q1 2026 | $21.18 | +405% |
| Q4 2025 | $10.52 | +201% |
| Q3 2025 | $7.59 | +984% |
| Q2 2025 | $5.57 | +$6.99 |
| Q1 2025 | $4.19 | +$7.64 |
| Q4 2024 | $3.49 | +$9.77 |
MU's earnings per share have climbed steadily: $74.33 over the past year, about 10 times what it earned the year before, and higher year over year for 10 quarters in a row.
CRCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $188.6M | +11% |
| Q2 2026 | $156.3M | -9.2% |
| Q1 2026 | $159.5M | -1.9% |
| Q4 2025 | $203.6M | -2.7% |
| Q3 2025 | $170.4M | +1.5% |
| Q2 2025 | $172.1M | +2.5% |
| Q1 2025 | $162.6M | -2.8% |
| Q4 2024 | $209.3M | -9.5% |
CRCT's revenue is recovering but still below its 2021 peak: $189M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +4.7 points |
| Q2 2026 | 30% | +13 points |
| Q1 2026 | 14% | -3.7 points |
| Q4 2025 | 6.8% | +0.2 points |
| Q3 2025 | 13% | +7 points |
| Q2 2025 | 17% | +1.7 points |
| Q1 2025 | 18% | +3 points |
| Q4 2024 | 6.6% | -0.5 points |
CRCT's operating margin was 18% last quarter, up 4.7 points from the same quarter a year ago.
MU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.2B | +379% |
| Q2 2026 | $41.5B | +346% |
| Q1 2026 | $23.9B | +196% |
| Q4 2025 | $13.6B | +57% |
| Q3 2025 | $11.3B | +46% |
| Q2 2025 | $9.3B | +37% |
| Q1 2025 | $8.1B | +38% |
| Q4 2024 | $8.7B | +84% |
MU has the edge over CRCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 81% | +48 points |
| Q2 2026 | 80% | +57 points |
| Q1 2026 | 68% | +46 points |
| Q4 2025 | 45% | +20 points |
| Q3 2025 | 32% | +13 points |
| Q2 2025 | 23% | +13 points |
| Q1 2025 | 22% | +19 points |
| Q4 2024 | 25% | +49 points |
MU has the edge over CRCT on profitability, with a higher operating margin.
CRCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $23.7M | +16% |
| Q2 2026 | $50.4M | +39% |
| Q1 2026 | $26.9M | -56% |
| Q4 2025 | $82.4M | -20% |
| Q3 2025 | $20.5M | -71% |
| Q2 2025 | $36.2M | +3.4% |
| Q1 2025 | $61.2M | +7.9% |
| Q4 2024 | $103.1M | +12% |
CRCT still generates free cash flow, though less than at its 2022 peak: $183M over the past year.
MU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.9B | +45543% |
| Q2 2026 | $17.6B | +951% |
| Q1 2026 | $5.5B | +$5.6B |
| Q4 2025 | $3B | +7853% |
| Q3 2025 | $72M | -75% |
| Q2 2025 | $1.7B | +322% |
| Q1 2025 | -$113M | +$52M |
| Q4 2024 | $38M | +$433M |
MU has the edge over CRCT on cash flow, with more consistent year-over-year improvement.
CRCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +1.7M shares |
| 1 year | -1.2% | -2.5M shares |
| 3 years | -3.5% | -7.6M shares |
| 5 years | -5.1% | -11.5M shares |
| Available history | -3.9% | -8.6M shares |
CRCT has the edge over MU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.9M |
| Q2 2026 | $7.5M |
| Q1 2026 | $12.3M |
| Q4 2025 | $5.7M |
| Q3 2025 | $2.4M |
| Q2 2025 | $4.7M |
| Q1 2025 | $12M |
| Q4 2024 | $8M |
CRCT spent $31M buying back its own shares over the past year, up 16% from the year before.
MU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -2M shares |
| 1 year | +1.6% | +18M shares |
| 3 years | +4.6% | +50M shares |
| 5 years | +0.2% | +2M shares |
| Available history | +1.2% | +14M shares |
MU has 1.1B diluted shares, up 1.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $350M |
| Q4 2025 | $300M |
| Q3 2024 | $300M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
MU has spent almost nothing on buybacks in the past year.
CRCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -2.1x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -1.6x | Net Cash |
| Q2 2025 | -2.7x | Net Cash |
| Q1 2025 | -2.3x | Net Cash |
| Q4 2024 | -2.2x | Net Cash |
CRCT has the edge over MU on leverage, with a lower net debt burden relative to earnings.
MU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
MU has more cash than debt.
CRCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.4 | Overbought |
| Stochastic | 74.8 | Neutral |
CRCT's weekly RSI is 76 (overbought) and its Stochastic is 75 (neutral).
MU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.1 | Neutral |
| Stochastic | 26.9 | Neutral |
MU's weekly RSI is 47 (neutral) and its Stochastic is 27 (neutral).
CRCT PE vs Technology Sector
| Metric | CRCT | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 28x | 32% below |
| PE % | 37 | 41 | 4 pts below |
CRCT is trading at 19x earnings, a 32% discount to the Technology sector's median of 28x.
MU PE vs Technology Sector
| Metric | MU | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 61% below |
| PE % | 18 | 35 | 17 pts below |
MU has the edge over CRCT on valuation relative to its sector.
CRCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.89 | 23% above |
| 20 week MA | $5.88 | 45% above |
| 50 week MA | $5.01 | 70% above |
| 100 week MA | $5.31 | 60% above |
| 200 week MA | $6.52 | 30% above |
CRCT has the edge over MU on trend strength, trading above more of its moving averages.
MU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $914.5 | 13% below |
| 20 week MA | $931.0 | 14% below |
| 50 week MA | $685.9 | 16% above |
| 100 week MA | $405.4 | 97% above |
| 200 week MA | $246.0 | 225% above |
MU has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 225% above its 200-week average.
CRCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.0 | $23.5 | +30% |
| 2022 | $23.5 | $10.1 | -57% |
| 2023 | $10.1 | $6.59 | -35% |
| 2024 | $6.59 | $5.75 | -13% |
| 2025 | $5.75 | $5.04 | -12% |
| 2026 YTD | $5.04 | $8.50 | +69% |
CRCT has finished four years in a row lower, and it's up 69% so far in 2026.
MU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.0 | $70.6 | +31% |
| 2021 | $70.6 | $94.4 | +34% |
| 2022 | $94.4 | $50.2 | -47% |
| 2023 | $50.2 | $85.3 | +70% |
| 2024 | $85.3 | $88.6 | +3.9% |
| 2025 | $88.6 | $284.8 | +221% |
| 2026 YTD | $284.8 | $798.4 | +180% |
MU has the edge over CRCT on returns for 2026, with the stronger performance.